Literature DB >> 15558213

Regulation and interactions in the activation of cell-associated plasminogen.

H Myöhänen1, A Vaheri.   

Abstract

The main components in plasminogen activation include plasminogen, tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), urokinase plasminogen activator receptor (uPAR), and plasminogen activator inhibitors-1 and -2 (PAI-1, PAI-2). These components are subject to extensive regulation and interactions with for example, pericellular adhesion molecules. Although uPA and tPA are quite similar in structure and have common inhibitors and physiological substrates, their physiological roles are distinct. Traditionally, the role of tPA has been in fibrinolysis and that of uPA in cell migration, especially in cancer cells. Recently several targets for tPA/plasmin have been found in neuronal tissues. The functional role of the PAIs is no longer simply to inhibit overexpressed plasminogen activators, and PAI-2 has an unidentified role in the regulation of cell death.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15558213     DOI: 10.1007/s00018-004-4230-9

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  64 in total

1.  Safety and efficacy of exercise training in various forms of pulmonary hypertension.

Authors:  Ekkehard Grünig; Mona Lichtblau; Nicola Ehlken; Hossein A Ghofrani; Frank Reichenberger; Gerd Staehler; Michael Halank; Christine Fischer; Hans-Jürgen Seyfarth; Hans Klose; Andreas Meyer; Stephan Sorichter; Heinrike Wilkens; Stephan Rosenkranz; Christian Opitz; Hanno Leuchte; Gabriele Karger; Rudolf Speich; Christian Nagel
Journal:  Eur Respir J       Date:  2012-02-09       Impact factor: 16.671

2.  [Mental distress and wish for psychosomatic treatment of patients with pulmonary hypertension].

Authors:  Astrid Larisch; Charlotte Neeb; Martina de Zwaan; Christian Pabst; Henning Tiede; Ardeschir Ghofrani; Karen Olsson; Marius Hoeper; Johannes Kruse
Journal:  Psychother Psychosom Med Psychol       Date:  2014-07-16

3.  The combination of exercise and respiratory training improves respiratory muscle function in pulmonary hypertension.

Authors:  Hans-Joachim Kabitz; Hinrich-Cordt Bremer; Anja Schwoerer; Florian Sonntag; Stephan Walterspacher; David Johannes Walker; Nicola Ehlken; Gerd Staehler; Wolfram Windisch; Ekkehard Grünig
Journal:  Lung       Date:  2013-12-13       Impact factor: 2.584

4.  Riociguat for the treatment of pulmonary arterial hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

5.  Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.

Authors:  Rajiv D Machado; Micheala A Aldred; Victoria James; Rachel E Harrison; Bhakti Patel; Edward C Schwalbe; Ekkehard Gruenig; Bart Janssen; Rolf Koehler; Werner Seeger; Oliver Eickelberg; Horst Olschewski; C Gregory Elliott; Eric Glissmeyer; John Carlquist; Miryoung Kim; Adam Torbicki; Anna Fijalkowska; Grzegorz Szewczyk; Jasmine Parma; Marc J Abramowicz; Nazzareno Galie; Hiroko Morisaki; Shingo Kyotani; Norifumi Nakanishi; Takayuki Morisaki; Marc Humbert; Gerald Simonneau; Olivier Sitbon; Florent Soubrier; Florence Coulet; Nicholas W Morrell; Richard C Trembath
Journal:  Hum Mutat       Date:  2006-02       Impact factor: 4.878

6.  Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Authors:  Gérald Simonneau; Lewis J Rubin; Nazzareno Galiè; Robyn J Barst; Thomas R Fleming; Adaani E Frost; Peter J Engel; Mordechai R Kramer; Gary Burgess; Lorraine Collings; Nandini Cossons; Olivier Sitbon; David B Badesch
Journal:  Ann Intern Med       Date:  2008-10-21       Impact factor: 25.391

7.  Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

Authors:  Karen M Olsson; Marion Delcroix; H Ardeschir Ghofrani; Henning Tiede; Doerte Huscher; Rudolf Speich; Ekkehard Grünig; Gerd Staehler; Stephan Rosenkranz; Michael Halank; Matthias Held; Tobias J Lange; Juergen Behr; Hans Klose; Martin Claussen; Ralf Ewert; Christian F Opitz; C Dario Vizza; Laura Scelsi; Anton Vonk-Noordegraaf; Harald Kaemmerer; J Simon R Gibbs; Gerry Coghlan; Joanna Pepke-Zaba; Uwe Schulz; Matthias Gorenflo; David Pittrow; Marius M Hoeper
Journal:  Circulation       Date:  2013-09-30       Impact factor: 29.690

8.  Exercise training in pulmonary arterial hypertension associated with connective tissue diseases.

Authors:  Ekkehard Grünig; Felicitas Maier; Nicola Ehlken; Christine Fischer; Mona Lichtblau; Norbert Blank; Christoph Fiehn; Frank Stöckl; Felix Prange; Gerd Staehler; Frank Reichenberger; Henning Tiede; Michael Halank; Hans-Jürgen Seyfarth; Simone Wagner; Christian Nagel
Journal:  Arthritis Res Ther       Date:  2012-06-18       Impact factor: 5.156

9.  Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations.

Authors:  Nicole Pfarr; Justyna Szamalek-Hoegel; Christine Fischer; Katrin Hinderhofer; Christian Nagel; Nicola Ehlken; Henning Tiede; Horst Olschewski; Frank Reichenberger; Ardeschir H A Ghofrani; Werner Seeger; Ekkehard Grünig
Journal:  Respir Res       Date:  2011-07-29

10.  Identification of a new intronic BMPR2-mutation and early diagnosis of heritable pulmonary arterial hypertension in a large family with mean clinical follow-up of 12 years.

Authors:  Katrin Hinderhofer; Christine Fischer; Nicole Pfarr; Justyna Szamalek-Hoegel; Mona Lichtblau; Christian Nagel; Benjamin Egenlauf; Nicola Ehlken; Ekkehard Grünig
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

View more
  35 in total

1.  Tissue-type plasminogen activator gene targets thrombolysis in atriums.

Authors:  Yongsheng Gong; Fajiu Wang; Xia Li; Zhixin Gao; Kailun Zhang; Chen Fan; Xingen Liu
Journal:  J Thromb Thrombolysis       Date:  2010-11       Impact factor: 2.300

2.  Plasminogen is a complement inhibitor.

Authors:  Diana Barthel; Susann Schindler; Peter F Zipfel
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

3.  Comparative proteomic analyses of Streptococcus suis serotype 2 cell wall-associated proteins.

Authors:  Yingchao Wang; Yuan Dang; Xinglong Wang; Hao Lu; Xiuran Wang; Xulong Lang; Xiaoyan Li; Shuzhang Feng; Fuxian Zhang; Linzhu Ren
Journal:  Curr Microbiol       Date:  2010-09-08       Impact factor: 2.188

4.  LRP-1 silencing prevents malignant cell invasion despite increased pericellular proteolytic activities.

Authors:  Stéphane Dedieu; Benoît Langlois; Jérôme Devy; Brice Sid; Patrick Henriet; Hervé Sartelet; Georges Bellon; Hervé Emonard; Laurent Martiny
Journal:  Mol Cell Biol       Date:  2008-03-03       Impact factor: 4.272

5.  Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.

Authors:  Chitta S Kasyapa; Padmaja Kunapuli; Lesleyann Hawthorn; John K Cowell
Journal:  Blood       Date:  2006-01-12       Impact factor: 22.113

6.  Temperature-induced changes in the lipopolysaccharide of Yersinia pestis affect plasminogen activation by the pla surface protease.

Authors:  Marjo Suomalainen; Leandro Araujo Lobo; Klaus Brandenburg; Buko Lindner; Ritva Virkola; Yuriy A Knirel; Andrey P Anisimov; Otto Holst; Timo K Korhonen
Journal:  Infect Immun       Date:  2010-04-05       Impact factor: 3.441

7.  The metalloprotease PrtV from Vibrio cholerae.

Authors:  Karolis Vaitkevicius; Pramod K Rompikuntal; Barbro Lindmark; Rimas Vaitkevicius; Tianyan Song; Sun N Wai
Journal:  FEBS J       Date:  2008-05-10       Impact factor: 5.542

8.  Immunogenic and plasminogen-binding surface-associated alpha-enolase of Trichomonas vaginalis.

Authors:  V Mundodi; A S Kucknoor; J F Alderete
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

9.  Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts.

Authors:  Ye He; Pei-Suen Tsou; Dinesh Khanna; Amr H Sawalha
Journal:  Ann Rheum Dis       Date:  2018-05-14       Impact factor: 19.103

10.  Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis.

Authors:  Julia Humphries; James A Gossage; Bijan Modarai; Kevin G Burnand; Thomas H Sisson; Colin Murdoch; Alberto Smith
Journal:  J Vasc Surg       Date:  2009-08-22       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.